Filing Flows › X4 Pharmaceuticals (XFOR) › Q3 2026 › vs Q3 2025
X4 Pharmaceuticals (XFOR) Q3 2026 vs Q3 2025 (year over year)
X4 Pharmaceuticals's revenue rose $1.2M (+75%) from $1.6M in Q3 2025 to $2.8M in Q3 2026. The biggest changes: Revenue from contracts with customers +$1.1M (+63%).
X4 Pharmaceuticals, Q3 2026: revenue $2.8M (+75% year over year), operating margin -714.0%, net loss $20.2M, operating cash flow −$20.2M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product revenue, net | $2.8M | $1.6M | $1.2M | +77% |
| License and other revenue | $106K | $199K | −$93K | -47% |
| Revenue from contracts with customers | $2.9M | $1.8M | $1.1M | +63% |
| Revenue | $2.8M | $1.6M | $1.2M | +75% |
| Other revenues (net loss) | $79K | $165K | −$86K | -52% |
| Net loss | $20.2M | $29.8M | −$9.6M | -32% |
| Costs & expenses | $23.0M | $31.4M | −$8.4M | -27% |
| Operating costs | $22.8M | $29.1M | −$6.3M | -22% |
| Interest & other, net | $204K | $2.3M | −$2.1M | -91% |
| Income tax | $3K | −$30K | $33K | — |
| Operating cash sources | $24.0M | $28.8M | −$4.8M | -17% |
| Depreciation & amortization | $331K | $223K | $108K | +48% |
| Share-based compensation | $3.5M | $760K | $2.7M | +361% |
| Cash used in operations | $20.2M | $27.8M | −$7.6M | -27% |
| Net loss absorbed | $20.2M | $29.8M | −$9.6M | -32% |
| Working capital & other | $3.8M | −$1.0M | $4.8M | — |
Questions
How much did X4 Pharmaceuticals's revenue grow year over year in Q3 2026?
X4 Pharmaceuticals's revenue rose $1.2M (+75%) from $1.6M in Q3 2025 to $2.8M in Q3 2026.
What drove X4 Pharmaceuticals's revenue change in Q3 2026?
Revenue from contracts with customers +$1.1M (+63%).